Source: GlobeNewswire Inc.
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract.
OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE, help manage knee OA pain.
“We are pleased DUROLANE is among the preferred options available to both Aetna™ Medicare Advantage members and physicians,” said Anthony Doyle, General Manager, Pain Treatments and Restorative Therapies for Bioventus. “Both now have access to a safe HA product that is proven to provide relief from knee OA pain.”
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Recent BVS News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 11:36:39 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:33:21 AM
- Bioventus Reports First Quarter Financial Results • GlobeNewswire Inc. • 05/07/2024 11:00:00 AM
- Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024 • GlobeNewswire Inc. • 04/29/2024 11:30:00 AM
- Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/12/2024 11:30:00 AM
- Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024 • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:05:27 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/22/2024 09:07:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 01:27:00 PM
- Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility • GlobeNewswire Inc. • 01/18/2024 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 10:10:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 09:52:30 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 09:39:42 PM
- Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole • GlobeNewswire Inc. • 01/12/2024 09:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/09/2024 01:55:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 01:00:29 PM
- Bioventus Names Robert Claypoole as President and Chief Executive Officer • GlobeNewswire Inc. • 12/19/2023 09:30:00 PM
- Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis • GlobeNewswire Inc. • 12/06/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 12:40:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 12:35:18 PM
- Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance • GlobeNewswire Inc. • 11/07/2023 12:00:00 PM
- Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023 • GlobeNewswire Inc. • 10/31/2023 11:00:00 AM
- Bioventus to Present at the Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/20/2023 01:52:45 AM
- Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference • GlobeNewswire Inc. • 09/06/2023 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 12:42:03 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM